First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials

AIMS: To assess the safety and pharmacokinetics of a new synthetic ozonide antimalarial, OZ439, in a first-in-man, double-blind study in healthy volunteers. METHODS: OZ439 was administered as single oral daily doses of a capsule formulation (50–1200 mg) or an oral dispersion (400–1600 mg, fed and fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Moehrle, Joerg J, Duparc, Stephan, Siethoff, Christoph, Giersbergen, Paul L M, Craft, J Carl, Arbe-Barnes, Sarah, Charman, Susan A, Gutierrez, Maria, Wittlin, Sergio, Vennerstrom, Jonathan L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Science Inc 2013
Materias:
Drug Safety
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558805/
https://www.ncbi.nlm.nih.gov/pubmed/22759078
http://dx.doi.org/10.1111/j.1365-2125.2012.04368.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558805/
https://www.ncbi.nlm.nih.gov/pubmed/22759078
http://dx.doi.org/10.1111/j.1365-2125.2012.04368.x

Ejemplares similares